Scarlet Therapeutics Announces Seed Financing to Advance Development of Therapeutic Red Blood Cell Platform
- Pioneering platform to generate novel therapies with potential to treat a wide range of diseases
- Financing led by Science Creates Ventures and Meltwind to fund development of the platform and initial product candidates
BRISTOL, UK, 23 May 2023 – Scarlet Therapeutics (“Scarlet”), a leader in red blood cell-based therapeutics, announces today that it has raised seed funding from Science Creates Ventures and Meltwind to enable it to advance development of its pioneering platform and build a pipeline of novel therapies to treat rare diseases.
